Homepage Top Section1

Oncorus, which is headquartered in Cambridge, Massachusetts, is an oncolytic virus company. It is engaged in advancing a portfolio of locally and systemically administered (IV) OV therapies based

The Dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) study demonstrated Farxiga’s potential with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the declining of heart

At present, the mRNA-1893 vaccine is being assessed in a phase 1 study to prevent Zika virus infection in healthy adults. The mRNA-1893 included an mRNA sequence that

Inrebic is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a

The late-stage study called PAOLA-1 evaluated Lynparza plus bevacizumab in the first line maintenance setting in comparison to bevacizumab alone in women with advanced ovarian cancer, irrespective of

In this regard, Boehringer Ingelheim and MD Anderson plan to set up a joint Virtual Research and Development Center to facilitate effective data sharing and analysis among themselves.

The United States District Court of New Jersey gave ruling against Sandoz over the validity of the two patents that describe and claim Enbrel and the methods for

As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its

Givosiran, which has been developed to be subcutaneously administered, targets aminolevulinic acid synthase 1 (ALAS1). According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially reduce